Chirfi Guindo - Apr 29, 2025 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Role
Chief Marketing Officer
Signature
/s/ Kelly Grez, as attorney-in-fact for Mr. Chirfi Guindo
Stock symbol
MRK
Transactions as of
Apr 29, 2025
Transactions value $
$0
Form type
4
Date filed
5/1/2025, 05:45 PM
Previous filing
Jan 29, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MRK Common Stock 69.8K Apr 29, 2025 Direct F1
holding MRK Common Stock-401(k) Plan 55.4 Apr 29, 2025 By 401(k) F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRK Restricted Stock Unit Award $0 +5.9K $0.00 5.9K Apr 29, 2025 Common Stock 5.9K Direct F3, F4
transaction MRK Stock Option (Right to Buy) Award $0 +26.9K $0.00 26.9K Apr 29, 2025 Common Stock 26.9K $84.71 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Holdings include shares acquired in dividend reinvestment transactions.
F2 Includes shares acquired and dividends earned through April 7, 2025 in the Merck U.S. Savings Plan, a 401(k) plan.
F3 Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F4 These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028.
F5 The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028.